Together, these data suggest that activation of the FOXO3a/AMPKα/pBeclin1 pathway contributes to the cell death induced by co-treatment with 3-BP and cetuximab in cetuximab-resistant human CRC cell lines. This evidence concerns the gene FOXO3 and colorectal carcinoma.